Main pretransplantation characteristics of patients
. | Autotransplant . | Allotransplant . |
|---|---|---|
| No. patients | 25 | 15 |
| Median age, y (range) | 48 (29-61) | 46 (29-55) |
| No. men | 17 | 7 |
| Median time from diagnosis to transplantation, mo (range) | 29 (11-183) | 30 (6-100) |
| Median no. lines of therapy (range) | 2 (1-5) | 2 (1-6) |
| Rai stage status at transplantation | ||
| 0 | 19 | 10 |
| I-II | 4 | 3 |
| III-IV | 2 | 2 |
| Bone marrow infiltration greater than 30% | 5/24 | 8/10 |
| IGVH mutational status* | ||
| Mutated | 4 | 7 |
| Unmutated | 18 | 7 |
| Conditioning regimen, no. patients | ||
| Myeloablative regimen | ||
| Cy/TBI | 21 | 13 |
| BEAM | 4 | — |
| Nonmyeloablative regimen | ||
| Flu/Melph | — | 1 |
| Flu/TBI | — | 1 |
. | Autotransplant . | Allotransplant . |
|---|---|---|
| No. patients | 25 | 15 |
| Median age, y (range) | 48 (29-61) | 46 (29-55) |
| No. men | 17 | 7 |
| Median time from diagnosis to transplantation, mo (range) | 29 (11-183) | 30 (6-100) |
| Median no. lines of therapy (range) | 2 (1-5) | 2 (1-6) |
| Rai stage status at transplantation | ||
| 0 | 19 | 10 |
| I-II | 4 | 3 |
| III-IV | 2 | 2 |
| Bone marrow infiltration greater than 30% | 5/24 | 8/10 |
| IGVH mutational status* | ||
| Mutated | 4 | 7 |
| Unmutated | 18 | 7 |
| Conditioning regimen, no. patients | ||
| Myeloablative regimen | ||
| Cy/TBI | 21 | 13 |
| BEAM | 4 | — |
| Nonmyeloablative regimen | ||
| Flu/Melph | — | 1 |
| Flu/TBI | — | 1 |
Cy/TBI indicates cyclophosphamide 120 mg/kg and total body irradiation (13 Gy); BEAM, bischloroethylnitrosourea (BCNU; 300 mg/m2, ×1 day), etoposide (200 mg/m2, ×4 days), cytarabine (400 mg/m2, ×4 days), melphalan (140 mg/m2, ×1 day); Flu/Melph, fludarabine (150 mg/m2) and melphalan (140 mg/m2); Flu/TBI, fludarabine 90 mg/m2 and total body irradiation (2 Gy); and —, not applicable.
Mutational status is available in 22 patients receiving an autologous stem cell transplant and in 14 receiving an allogeneic stem cell transplant.